SGLT2 inhibitors in autosomal dominant polycystic kidney disease: rationale, evidence gaps, and ongoing clinical trials
International Urology and Nephrology · 12.08.2026
DOI: 10.1007/s11255-026-05340-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Urology and Nephrology, online erschienen am 12.08.2026. Verfasst von Leonardo Spatola und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology and Dialysis Unit, "Sant'Antonio" Hospital, ASPTrapani, Trapani, Italy. leonardospatola9@gmail.com. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Autosomal dominant polycystic kidney disease (ADPKD) remains the leading inherited cause of chronic kidney disease (CKD), with specific management largely relying on the approval of the selective vasopressin V2 receptor antagonist, tolvaptan, in recent years. However, the administration of tolvaptan is associated with several potential risks, including aquaretic side effects, dehydration, and acute kidney and liver injuries, highlighting the need for careful consideration of the optimal dosage. In this context, there has been increasing interest in the use of SGLT2 inhibitors for both diabetic and non-diabetic chronic kidney disease given their cardio- and nephroprotective roles, as well as their potential to delay progression to end-stage renal disease. Nevertheless, the exclusion of ADPKD patients from randomized controlled trials (RCTs) involving CKD patients receiving SGLT2 inhibitors-due to concerns about eGFR decline, cyst growth, and increased total kidney volume-has created a gap in evidence and uncertainty. Available observational studies indicate both beneficial and adverse effects, while ongoing trials aim to provide more definitive evidence on the safety and efficacy of SGLT2 inhibitors in this inherited CKD population. Therefore, this review aims to focus on the current treatment options for ADPKD patients and the promising role of SGLT2 inhibitors, drawing on the available literature and ongoing RCTs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology and Dialysis Unit, "Sant'Antonio" Hospital, ASPTrapani, Trapani, Italy. leonardospatola9@gmail.com.
- Nephrology and Dialysis Unit, "Cannizzaro" Emergency Hospital, Catania, Italy.
- Advanced School of Ultrasound in Nephrology - SIUMB, Catania, Italy.
- Nephrology and Dialysis Unit, "Sant'Antonio" Hospital, ASPTrapani, Trapani, Italy.
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
- Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, "Careggi" Hospital, Florence, Italy.
Zitieren
APA
Spatola, L., Maccarrone, R., Oddo, G., Granata, S., Zeiler, M., & Granata, A. (2026). SGLT2 inhibitors in autosomal dominant polycystic kidney disease: rationale, evidence gaps, and ongoing clinical trials. International Urology and Nephrology. https://doi.org/10.1007/s11255-026-05340-9
Vancouver
Spatola L, Maccarrone R, Oddo G, Granata S, Zeiler M, Granata A. SGLT2 inhibitors in autosomal dominant polycystic kidney disease: rationale, evidence gaps, and ongoing clinical trials. International Urology and Nephrology. 2026. doi:10.1007/s11255-026-05340-9
BibTeX
@article{Spatola2026,
author = {Spatola, Leonardo and Maccarrone, Rosario and Oddo, Gaspare and Granata, Salvatore and Zeiler, Matthias and Granata, Antonio},
title = {SGLT2 inhibitors in autosomal dominant polycystic kidney disease: rationale, evidence gaps, and ongoing clinical trials},
journal = {International Urology and Nephrology},
year = {2026},
doi = {10.1007/s11255-026-05340-9}
}
EUVIMED